论文部分内容阅读
目的对比卡培他滨联合紫杉醇与替吉奥联合紫杉醇治疗弥漫型晚期胃癌患者的疗效。方法收集山西省肿瘤医院2009年6月至2015年6月之间54例弥漫型晚期胃癌患者病例,其中卡培他滨联合紫杉醇治疗方案28例,替吉奥联合紫杉醇治疗26例,观察患者的总生存期及无进展生存期情况。采用Kaplan Meier描绘生存曲线;Log-rank法检验生存期。结果弥漫型晚期胃癌患者接受卡培他滨联合紫杉醇化疗方案的中位生存时间为9.5个月(95%CI:7.9~11.0个月),接受替吉奥联合紫杉醇化疗方案的中位生存时间为10.5个月(95%CI:9.5~11.5个月)。接受卡培他滨联合紫杉醇化疗方案的中位无进展生存期为5.4个月(95%CI:4.3~6.5个月),接受替吉奥联合紫杉醇化疗方案的中位无进展生存期为7.0个月(95%CI:6.7~7.3个月)。采用Kaplan Meier描绘生存曲线。经Log-rank法检验弥漫型晚期胃癌患者接受替吉奥联合紫杉醇方案的总生存期、无进展生存期显著短于卡培他滨联合紫杉醇方案(P<0.05)。结论弥漫型晚期胃癌患者接受替吉奥联合紫杉醇方案可获得更多生存获益。
Objective To compare the curative effect of capecitabine combined with paclitaxel and tegaserod combined with paclitaxel in patients with diffuse advanced gastric cancer. Methods Totally 54 patients with diffuse advanced gastric cancer were collected from Shanxi Cancer Hospital from June 2009 to June 2015. Among them, 28 were treated with capecitabine and paclitaxel, 26 were treated with tegaserod and paclitaxel, Total survival and progression-free survival. Survival curves were plotted using Kaplan Meier and Log-rank test. Results The median survival time of patients with diffuse advanced gastric cancer receiving capecitabine combined with paclitaxel chemotherapy was 9.5 months (95% CI: 7.9-11.0 months). The median survival time of patients receiving chemotherapy with tegaserod plus paclitaxel was 10.5 months (95% CI: 9.5 to 11.5 months). The median progression-free survival for patients receiving capecitabine plus paclitaxel was 5.4 months (95% CI: 4.3 to 6.5 months) and 7.0 for embolic chemotherapy plus paclitaxel Month (95% CI: 6.7 to 7.3 months). Survival curves were plotted using Kaplan Meier. The Log-rank test for patients with diffuse advanced gastric cancer received the tegasergic combination of paclitaxel, the overall survival and progression-free survival was significantly shorter than capecitabine combined with paclitaxel (P <0.05). Conclusions Patients with diffuse advanced gastric cancer receive more treatment benefit for treatment of tegaserod combined with paclitaxel.